Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 3 | 5 | 8 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 8 | 12 | 20 |
| 2011 | 6 | 7 | 13 |
| 2012 | 9 | 6 | 15 |
| 2013 | 8 | 14 | 22 |
| 2014 | 18 | 8 | 26 |
| 2015 | 16 | 5 | 21 |
| 2016 | 20 | 12 | 32 |
| 2017 | 15 | 13 | 28 |
| 2018 | 22 | 6 | 28 |
| 2019 | 14 | 12 | 26 |
| 2020 | 14 | 11 | 25 |
| 2021 | 22 | 12 | 34 |
| 2022 | 2 | 18 | 20 |
| 2023 | 3 | 19 | 22 |
| 2024 | 19 | 7 | 26 |
| 2025 | 27 | 8 | 35 |
| 2026 | 22 | 1 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clin Cancer Res. 2026 Nov 02; 32(21):4956-4974.
-
Design, Synthesis, and Pharmacological Profiling of Serine/Threonine Kinase 33 (STK33) Inhibitors for Nonhormonal Male Contraception. J Med Chem. 2026 Oct 22; 69(20):23564-23584.
-
Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood Adv. 2026 09 08; 10(17):5821-5827.
-
Identification of potent inhibitors of JUN N-terminal kinases for treatment of endometriosis and associated pain. Proc Natl Acad Sci U S A. 2026 Aug 25; 123(34):e2607561123.
-
Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia. Nat Cell Biol. 2026 Aug; 28(8):1715-1727.
-
Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation. Cancer Lett. 2026 Oct 28; 659:218771.
-
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2?-?metastatic breast cancer: a single-institution experience. J Egypt Natl Canc Inst. 2026 Jul 28; 38(1).
-
Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2026 09; 73(9):e70525.
-
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation. Clin Pharmacokinet. 2026 Sep; 65(9):1389-1403.
-
Tolebrutinib liver safety: A detailed overview. Mult Scler Relat Disord. 2026 Sep; 113:107404.